IN VITRO AND IN VIVO ANTIFUNGAL ACTIVITY OF ALKALOID 3,5-bis(4,4”-dimethoxy-[1,1’:2’,1”-terphenyl]-4’-yl)-4H-pyrazole-4,4-diol FROM DERRIS INDICA (LAM) BENNET SEEDS

NUZHAT TABASSUM1, VIDYASAGAR G. M.1,*, RAGHUNANDAN D2, SHIVAKUMAR F2
1Department of Post-Graduate Studies and Research in Botany, Medicinal Plants and Microbiology Research Laboratory, Gulbarga University, Kalaburagi, Karnataka, India. 2Department of Pharmaceutical and Nano Chemistry, Matoshree Taradevi Rampure Institute of Pharmaceutical Sciences, Kalaburagi, Karnataka, India. Email: gmvidyasagar@rediffmail.com

Received: 10 March 2021, Revised and Accepted: 10 May 2021

ABSTRACT

Objectives: The aim of the present study is to isolate an antifungal compound from Derris indica (Lam) Bennett seed oil with various solvents and evaluation of its antifungal activity against Candida species.

Methods: D. indica seed hexane extract was tested against Trichophyton rubrum, Trichophyton tonsurans and Candida albicans. Hexane extract was fractioned using column chromatography (CC). Isolated compound D1 was identified and characterized using ultraviolet, Fourier-transform infrared, 'HNMR, and mass spectroscopy. In vitro evaluation of D1 carried out against 12 Candida strains. In vivo evaluation of D1 carried out against T. rubrum, T. tonsurans, and C. albicans using an excision wound healing model in male Wistar rats.

Results: Different concentrations of hexane extract showed antimicrobial activity against tested microorganism with varying minimum inhibitory concentration values. On fractionation with hexane-petroleum ether through CC, it yielded a crystalline fraction. Compound D1 characterized as a 3,5-bis([4,4’-dimethoxy-[1,1’:2’,1”-terphenyl]-4’-yl]-4H-pyrazole-4,4-diol. A novel alkaloid compound from D. indica is a new report and proved to be inhibitory against C. albicans MTCC 3017 (14.83±0.28), MTCC 1637 (16.0±0.00), Candida glabrata MTCC 3014 (16.83±0.28) and MTCC 3014 (16.66±0.57), Candida tropicalis MTCC 230 (20.0±0.00), MTCC 1406 (12.33±0.57). C. glabrata MTCC 3981 was found to be resistant to the compound. In vivo studies showed no visual symptoms at the end of treatment indicating the therapeutic property of the compound.

Conclusion: The D1 was found to be effective against human fungal pathogens and can be used as a base molecule in designing new antifungal drugs.

Keywords: Derris indica, Seed oil, Alkaloid compound, In vitro, In vivo studies.

© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) DOI: http://dx.doi.org/10.22159/ajpcr.2021v14i6.41383. Journal homepage: https://innovareacademic.in/journals/index.php/ajpcr

INTRODUCTION

Derris indica belonging to the family Fabaceae (Papilionaceae) is a medium-sized evergreen, fast-growing, glabrous, and deciduous tree widely distributed in the region of Southeast Asia and Pacific Islands [1]. It is one of the nitrogen fixing tree producing seeds containing 30–40% oil [2]. This versatile medicinal plant is the unique source of various types of chemical compounds [3]. The plant is reported to produce a wide range of flavonoids with antimicrobial activity [4-16]. The seeds contain 13.5% mucilage, traces of essential oil and complex amino acids, termed glabrin. Four furanoflavonones (karanjin, pongapin (C11H12O6), kanjone (C12H14O6), and pongaglabol (C16H16O4)), have been isolated from Indian Karanja seed [17]. Three furanoflavonoids (Pongamosides A, B, and C) and a flavonol, glucoside, and pongamoside D have been reported from n-butanol-soluble fraction of ethanolic extract of D. indica fruit [7]. Pongaglabol, hydroxyfuranoflavone, aurantiamide acetate, four furanoflavonones (karanjin, lancheolatin B, kanjone, and pinnatin) and a rarely occurring modified phenylalanine dipeptide have been isolated [18]. Conventionally, the plant has been used in the treatment of several ailments. The bark is used in pile, leave in medicated bath and rheumatic pains, seeds in hypertension, bronchitis, whooping cough, skin diseases and rheumatic arthritis, roots in cleaning gums, teeth, ulcers and gonorrhea, and flowers are used in the treatment of diabetes [19].

Nowadays, antibiotics have created an enormous clinical problem in the treatment of infectious diseases [20]. Skin fungal infections are predictably grouped into superficial, subcutaneous and systemic infections [21]. According to the World Health Organization survey on the incidence of dermatophytic infection, about 20% worldwide populations have suffered with cutaneous infections [22]. Unlike other fungi, dermatophytes are communicable and cause infections in healthy, immune-competent individuals as well as in those with immune dysfunction [23]. Herbal drugs have great need and play a key role in health-care systems [24]. Therapeutic property of herbal drugs is due to the presence of active constituents such as alkaloids, glycosides, saponins, terpenoids, lactones, phenols, and flavonoids present in different parts of plants [25,26]. D. indica is a unique source of various phytoconstituents belonging to alkaloids, glycosides, flavonoids, fixed oils, and carbohydrate responsible for various activities [27]. Previously, numerous authors reported the presence of various phytoconstituents in seeds [28-31]. These compounds have many interesting pharmacological and industrial applications. The aim of the present study is to isolate an antifungal compound from D. indica seeds.

METHODS

Collection of plant material
D. indica mature seeds collected from Gulbarga University campus and local areas of Kalaburagi district, Karnataka, India, and authentically identified using herbarium deposited in the Department of Botany, Gulbarga University, Kalaburagi, Karnataka, India, with voucher specimen number HUGC-206 and literatures [32-34].

Preparation of extract
Seeds were washed with water, dried for 4–5 days at room temperature and pulverized to fine powder (particle size 2 mm) and extracted...
with Soxhlet extractor (40°C) with hexane for 12 h. The extracted oil obtained was condensed and filtered using Whatman No. 1 filter paper, evaporated in vacuo, percent of the extract was recorded and stored in an airtight screw-capped bottle and stored at 4°C in the refrigerator for further use.

**Fractionation and identification**

Hexane extract (10 mg) was dissolved in 100 ml of hexane and used as a test solution. It was subjected to standard methods of phytochemical analysis to detect the presence of phytoconstituents [35-38] and also physicochemical analysis, namely, color, boiling point, solubility, estimation, iodine value, acid value, and saponification value. The column chromatography (CC) over silica gel-H of mesh size 60-120 μ (HiMedia, Mumbai) using eluent mixtures of hexane, pet ether, chloroform, ethyl acetate, and methanol (5d-fine, Mumbai) of increasing polarity at a flow rate of 1 ml/min was employed. Each 5 ml of 16 fractions were collected into a plate. Active fraction from antifungal assay, fraction-1 using solvent system hexane-petroleum ether (6:4, v/v) was checked by the thin-layer chromatography (TLC) coated silica gel-G, to know the purity of fractions. TLC plates were prepared as formulated [39] TLC plates were visualized by spraying HSO₃ (50%), heating for 8-10 min at 80°C.

Fraction 1 was purified by recrystallization to give pure compound. The melting point was determined by Thiele melting point apparatus. The obtained pure compound was subjected to liquid chromatography-mass spectrometry (LC-MS) analysis to determine the corresponding molecular ions present in the compound and analyzed in a Shimadzu LC-MS model 2010 A in JEOL Model GS-5000 spectrophotometer with CDCl₃ (denaturated chloroform, DMSO) as the solvent. An ultraviolet (UV)/visible spectrum was obtained using a 5704SS ELICO spectrophotometer in the range of 200-800 nm wavelengths. Fourier-transform infrared (FTIR) spectrum was measured using KBr discs on an ATR FTIR spectrometer. The NMR was performed to determine the structure of an isolated pure compound. 1H NMR was recorded using Bruker AM-400 NMR spectrometer using TMS (Tetramethyl saline) as an internal reference at 400.137 MHz in CDCl₃

**Biological assay**

**Test organisms**

Trichohyton rubrum and Trichophyton tonsurans were collected from Mahadevappa Rampure Medical College, Kalaburagi and 12 Candida species, namely, Candida albicans MTCC 183, MTCC 3017, and MTCC 1637, Candida glabrata MTCC 3814, MTCC 3014, and MTCC 3981, Candida haemulonii MTCC 1966, MTCC 2766, and MTCC 8303, and Candida tropicalis MTCC 230, MTCC 1406, and MTCC 2795 were obtained from Institute of Microbial Technology, Chandigarh, India. The fungal cultures were maintained on Sabouraud Dextrose Agar (SDA) medium supplemented with Chloramphenicol and Streptomycin sulfate and subcultured on Potato Dextrose Agar every 15 days to prevent pleomorphic transformations. Yeast peptone dextrose (YPD) agar media were used for the assay.

**Drug preparation**

The isolated compound D1 diluted in 1% (v/v) Dimethyl formamide (DMF) at a concentration of 5 mg/ml. Stock solution of the drug powder, Ketoconazole was prepared in 1% (v/v) DMF at a concentration of 1mg/ml and stored at −20°C and used for the assay.

**Agar well diffusion assay**

Antifungal activity of the D. indica hexane extract was evaluated against T. rubrum and C. albicans. The fungal cell suspensions were prepared according to the following procedure. Fungal lawn was prepared using 5 days old culture strain. The fungal strains were suspended in a saline solution (0.85% NaCl) and adjusted to a turbidity of 0.5 MacFarland standards (108 CFU/ml) and used for the assay. The determination of minimum inhibitory concentration (MIC) of extract was performed by serial dilution (0.6, 1.2, 2.5, 5, 10, 20, and 40 mg/ml) in DMF (v/v) against tested organisms by agar well diffusion method [40]. The petri dishes were prepared in triplicates and maintained at 37°C for 48 h. The diameter of zones of inhibition was measured in mm and statistically analyzed and expressed as mean (n = 3) ± standard deviation (SD). DMF used as negative control and Ketoconazole (1000 µg/ml) as positive control. Similarly in vitro antifungal testing of isolated compound D1 was carried out against Candida species by above mentioned method on YPD agar plates.

**Excision wound healing from isolated compound D1**

**Animals**

Wistar male rats weighing about 250 g were used for wound healing study. Animals were maintained in propylene cages at room temperature 22±2°C, relative humidity ~60% in a 12-h light-dark cycle. Rats were given pelleted diet and tap water ad libitum. Animal experiment procedures were carried out in accordance with the guidelines of the Public Health Service Policy on Human Care and use of laboratory animals (Matsoshree Taradevi Rampure Institute of Pharmaceutical Sciences, Kalaburagi) and the protocol was approved by the institutional animal ethical committee (HKE/COP/AEC/66/2013) for care and use.

**Analysis of non-harmful effects**

To determine the non-harmful effect of the effective compound, male Wistar rats (250 g) were used and maintained under the same condition as described above. Wistar rats were randomly divided into five groups and each group containing five rats. According to concentration of applied compound investigated. The compound considered as non-harmful if all the five animals in a group survive after 48 h application. About 0.5 ml of prepared stock solution of the effective compound was diluted in ethanol (0.01, 0.1, 0.2, 0.3, and 0.4%, vol/vol) and injected intraperitoneally. About 0.1% concentration was non-harmful to the animals and selected to use for further investigation.

**Wound healing activity**

Excision wound was used to evaluate the wound healing activity of compound D1. The rats were inflicted excision wound as described [41,42]. The groups were divided as: 1st group-untreated animals served as a control, 2nd group-animals treated with standard, 3rd group-treated with compound against T. rubrum, 4th group-treated with compound against C. albicans, and 5th group treated with compound against C. albicans. 4 cm² areas were cleaned and depilated on the back of each animal. The inoculum was applied on the back of the animals immediately after depletion and left for 3 days. The establishment of active infection was confirmed on day 4 by isolation of the pathogens from skin scales cultured and by visual examination on 8–10 days. The treatment was initiated on animals with active infections, from the 20th day post-inoculation and continued till complete recovery from infection was achieved. Treatment started, and ointment contained 0.1% (vol/vol) of compound, separately mixed in petroleum jelly, applied once daily on infected area and scored visually for inflammation and scaling. The commercial fungicide ketoconazole used as a control. Clinical assessment of inoculated skin area was performed using a modified lesion score from 0 to 4 as indicated. The recorded score 0 indicates no visible lesion; score 1 few slightly erythematous lesions; score 2 well-defined vesicles; score 3 large areas of marked redness, scaling, blade patches; and score 4 mycotic foci well developed with ulceration. The lesion was scored from 1, 3, 10, 20, 30, and 40 days. The presence of the pathogens was confirmed by cultivation of skin scales from infected loci on SDA plates each day.

**RESULTS AND DISCUSSION**

Agar well diffusion assay

D. indica seed hexane extract was first subjected to agar well diffusion assay to identify the presence of potential antifungal compounds. The
inhibitory activity on tested fungi was quantified by the diameter of zones of inhibition. MIC extract at different concentration showed antifungal activity (6.62–40 mg/ml) against pathogenic fungi C. albicans and T. rubrum with varying MIC values and summarized (Table 1). Among all the concentrations maximum zones of inhibition showed 18.83±0.28 (C. albicans) and 16.83±0.28 (T. rubrum) at 40 mg/ml and found to be more effective concentration. Several researchers reported that alkaloids, phenols, triterpenoids, glycosides, and tannins have high potential that could be developed as antimicrobial compounds [43,44]. The result observed in the present study suggests that the hexane extract inhibit the growth of microbes by the presence of these phytochemicals which are responsible to inhibit the fungal metabolism. A varied level of broad-spectrum antimicrobial activity was observed by authors from various parts of D. indica on fractionation with different solvents and suggested the use of fatty oil of D. indica plant as antimicrobial drugs against pathogenic bacteria and fungi [45-48].

### Table 1: MIC of *D. indica* seed extract

| S. No. | Botanical name and part used | Family | Zone of inhibition |
|-------|-------------------------------|--------|--------------------|
| 1.    | *Derris indica* (Seeds extract) | Fabaceae | C. albicans |
|       |                               |        | 18.83±0.28 |
|       |                               |        | 16.83±0.28 |
|       |                               |        | 13.5±0.5 |
|       |                               |        | 12.83±0.28 |
|       |                               |        | 11.16±0.28 |
|       |                               |        | 10.83±0.28 |
|       |                               |        | 12.0±0.0 |
| 2.    | Positive control               |        | Ketacozalo |
|       |                               |        | 24.0±0.0 |
| 3.    | Negative control               |        | DMF | NA |

**D. indica:** Derris indica, *T. rubrum:* Trichophyton rubrum, MIC: Minimum inhibitory concentration, DMF: Dimethyl formamide

### Fractionation and identification

Phytochemical screening tests were conducted to determine the presence of various secondary metabolites present in *D. indica* hexane seeds extract. Phytochemical screening results revealed the presence of steroids, glycosides, flavonoids, alkaloids, and saponins in the extracts [37,38]. Plant was collected based on their ethnopharmacological significance and used as traditional medicine by herbal practitioners and local people. Detailed information was gathered by several interviews [49]. In our previous study, phytochemical screening tests were conducted to determine the presence of various secondary metabolites present in *D. indica* seeds hexane extract and results were compared with reported literature data found to be similar with chloroform extract [50,51]. The results of physicochemical characterizations of hexane extract were found to be soluble in hexane, petroleum ether, chloroform, ethyl acetate, methanol, DMF and DMSO whereas insoluble in water. The extract was brown color with a boiling point (210°C) and the content of hexane extract was weighed (49%). This value was more or less similar to the previously reported literatures which confirmed that seeds are a rich source of lipids [52,53]. The iodine value of the oil indicates that the amount of saturated fatty acid, and iodine value (119.02 mg of KOH/g) acid value (2.0 mg KOH/g), and saponification value (181.9 mg KOH/g), respectively. It is evident from the results of phytochemical studies that seeds are rich source of flavonoids, alkaloids, glycosides, and saponins of pharmacological importance. Thus, an attempt was made here to isolate some of these phytochemical compounds from the seeds of *D. indica* by CC and purified with the help of TLC.

In the present investigation isolated compound D1 was obtained as pale yellow rod shaped crystals (15.5 μm length). There are many reports of isolation of compounds from *D. indica* seed oil in crystal form such as Pongamol [30], Pongapin [54], and Pongol [55]. Further, purity of the fraction was checked by TLC using solvent systems [Hexane-petroleum ether (6:4, v/v)]. HRF value (58.28), appeared as a single discrete spot and melting point recorded as 148–150°C. Further, pure fraction was subjected for detailed spectroscopic studies. The UV spectrum of compound D1 showed UV−λmax nm wavelength 665.0 and absorbance at 0.600 ranges indicates the presence of the chromophoric group with an extended conjugation (Fig. 1). The FTIR spectrum reveals the presence of Hydroxyl group (OH) at 3305 cm−1 broad main absorption band and the additional moderate to intense band 1063−m1, 1270−m1, 1361−m1, 1443−m1, and 1511−m1 is present in between the ranges 600−m1 and 1600−m1. Band 2929 cm−1 is due to stretching (C-H) and 1606 cm−1 is for C=N group stretching (Fig. 2). Its molecular formula was assumed to be C36H30N6O6 and molecular weight is 676.77. The mass spectrum indicated the molecular ion peak at m/z 676 and base ion peak at m/z 258 (Figs. 3 and 4).

The 1H NMR spectrum of D1 showed signal at δ8 8.21 (1H, d, J = 4 Hz), and δ8 11.15 (1H, δ8 7.77 (d), multiplet between δ8 7.58–7.54 and δ8 8.21 (1H, d, J = 4Hz), 7.77 (d), and 7.58–7.54 and 8.21 (1H, d, J = 4Hz), δ8 1.72 (s) to hydroxyl protons suggested that compound D1 is alkaloid derivatives. Spectroscopic data support the proposed structure D1 (Fig. 5). The structure of isolated compound was established on the basis of spectroscopic studies. This is the first report that crystalline alkaloid had been found as naturally occurring compound from *D. indica* seed oil. The physicochemical properties and spectroscopic

---

**Image:**

- Fig. 1: Ultraviolet spectrum of isolated compound from *Derris indica* seed oil
- Fig. 2: Fourier-transform infrared spectrum of isolated compound from *Derris indica* seed oil
data indicated that compound D1 is an alkaloid and characterized as, 3,5-bis(4,4'-dimethoxy-[1,1':2,1''-terphenyl]-4'-yl) -4H-pyrazole-

| Organism     | Strains of MTCC | K          | D1          | C          |
|--------------|-----------------|------------|-------------|------------|
| C. albicans  | 183             | 23.83±0.28 | 12.16±0.28  | -          |
|              | 1637            | 19.96±0.28 | 16.0±0.0    | -          |
|              | 3017            | 24.0±0.0   | 14.83±0.28  | -          |
| C. glabrata  | 3814            | 23.66±0.28 | 16.83±0.28  | -          |
|              | 3014            | 20.0±0.0   | 16.66±0.57  | -          |
|              | 2766            | 16.66±0.28 | 8.0±0.0     | -          |
| C. haemulonii| 1966            | 13.8±0.28  | 8.16±0.28   | -          |
|              | 2766            | 16.66±0.28 | 8.0±0.0     | -          |
| C. tropicalis| 230             | 24.0±0.0   | 20.0±0.0    | -          |
|              | 1406            | 20.0±0.0   | 12.33±0.57  | -          |
|              | 2795            | 16.83±0.28 | 6.33±0.57   | -          |

C. albicans: Candida albicans, C. glabrata: Candida glabrata, C. haemulonii: Candida haemulonii, C. tropicalis: Candida tropicalis

Table 3: In vivo studies of isolated compound D1 against pathogenic fungi on male Wistar rats

| No. of treated days | Group I control | Group II standard T. rubrum | Group III T. tonsurans | Group IV T. albicans |
|---------------------|-----------------|-----------------------------|------------------------|----------------------|
| 1<sup>st</sup> day  | -               | -                           | -                      | -                    |
| 3<sup>rd</sup> day  | 1               | 1                           | 1                      | 1                    |
| 5<sup>th</sup> day  | 2               | 1                           | 2                      | 3                    |
| 10<sup>th</sup> day | 3               | 0                           | 2                      | 2                    |
| 20<sup>th</sup> day| 4               | 0                           | 1                      | 1                    |
| 30<sup>th</sup> day| 3               | 0                           | 1                      | 0                    |
| 40<sup>th</sup> day| 3               | 0                           | 0                      | 0                    |
| 45<sup>th</sup> day| 3               | 0                           | 0                      | 0                    |

T. rubrum: Trichophyton rubrum, T. tonsurans: Trichophyton tonsurans, C. albicans: Candida albicans

Fig. 3: Liquid chromatographic spectrum of isolated compound from Derris indica seed oil

Anticandidal activity of isolated compound D1

The isolated compound D1 was tested against Candida albicans, C. glabrata, and C. tropicalis is summarized in Table 2. The purpose of present study was to check the isolated compound D1 (5mg/ml) against 12 Candida strains obtained from (MTCC) Institute of Microbial Technology, Chandigarh, India, and to evaluate their sensitivity or resistance to currently used antifungal agents. A strong anticandidal activity was observed against C. tropicalis MTCC 230 (20.0±0.0), C. glabrata MTCC 3814 (16.83±0.28) and MTCC 3014 (16.66±0.57), and C. albicans MTCC 1637 (16.0±0.0). Furthermore, D1 also showed moderate activity against C. tropicalis MTCC 1406 (12.33±0.57) and C. albicans MTCC 3017 (14.83±0.28).

Interestingly C. glabrata MTCC 3981 was found to be resistance against compound and found to be very less effective against Ketoconazole (11.33±1.15) (Fig. 6). C. tropicalis MTCC 230 (20.0±0.0) inhibited 80% while compared with standard (24.0±0.0), followed by another strain of C. tropicalis MTCC 1406 (12.33±0.57). showed less activity compared with strain MTCC 230 (20.0±0.0). Ketoconazole (1mg/ml) was used as a positive control (Fig. 6). This observation was found to be similar with reported literatures from essential oils of different plants [46-68] and confirmed while comparing with works reported from lemongrass oil inhibits 80% and found to be most active against human dermatophytic strains and was confirmed by the antifungal activity against C. albicans and also from reports by traditional users of lemongrass against ring worm infections [87,88]. Several studies have revealed that alkaloids, saponins, tannins, flavonoids, and phenolic compounds possess antimicrobial activities [89]. According to some reports, alkaloids, a class of natural products is complex heterocyclic nitrogenous compounds commonly found to possess antimicrobial properties [90]. Our work proves to be quite interesting due to the presence of alkaloids, flavonoids, and saponins, important classes of bioactive phytochemicals in D. indica seed oil and compound D1. Further, it provides scientific validation for usage of the plant extracts in folk medicine in our region [49,50].

Fig. 4: Mass spectrum of isolated compound from Derris indica seed oil
The genus Candida includes several species concerned in human pathology such as C. albicans, C. tropicalis, Candida parapsilosis, C. glabrata, Candida krusei, Candida lusitaniae, Candida kefyr, Candida guilliermondii, and Candida dubliniensis [94]. Among this, C. albicans is extremely known to be the most common cause of mucosal yeast infection [92,93]. People of all ages are affected by skin infections; the causative agents may be yeast cell C. albicans, mold, and dermatophytes [94]. Importance of fungal infections, the difficulties in their treatment and the increase in resistance to antifungal agents have increased research on therapeutic substitutes. Further in vivo studies were undertaken to elucidate the exact mechanism of action by which compound exerts their antifungal effect.

K- Ketoconazole, C- Control, D1- D. indica isolated compound

Excision wound healing from isolated compound D1

The antifungal and therapeutic potential of the isolated compound D1 was evaluated in vivo by using an excision wound healing model on male Wistar rats. No harmful activity was observed for 0.1% extracts in toxicological test; hence, this concentration was used for further investigation. For in vivo experiment fungal pathogens such as

![Fig. 5: Structure of 3,5-bis(4,4''-dimethoxy-[1,1':2',1''-terphenyl]-4'-yl)-4H-pyrazole-4,4-diol](image)

![Fig. 6: In vitro susceptibility assay of isolated pure compounds D1 against Candida species. 1. (+ve control 1mg/ml), 2. (-ve control) and 3. (Isolated compounds D1 5 mg/ml). Candida albicans. a (MTCC 3017), b (MTCC 1637) and c (MTCC 183). Candida tropicalis. d (MTCC 2795), e (MTCC 1406) and f (MTCC 230). Candida gaigantae. g (MTCC 3981), h (MTCC 3841) and i (MTCC 3019). Candida haemulonii. j (MTCC 8303), k (MTCC 1966), and l (MTCC 2766)](image)
The results of in vivo study are summarized in Table 3. The treatment was started from the 5th day of the experiment. During the study, it was found that animals induced with fungi C. albicans treated with isolated compound was completely cured after 30 days. T. rubrum induced fungi takes 40 days to cure wounds completely. The dermatomycete T. tonsurans which showed similar results while compare with the rats induced by T. rubrum. Compound tested for this experiment observed no visual symptoms at the end of the treatment and showed therapeutic activity. Compound showed antifungal activity against C. albicans and T. tonsurans after 30 days and against T. rubrum after 40 days of treatment. The results demonstrated significant wound healing activity of the tested compound as compared to the established drug ketoconazole. The animals treated with ketoconazole showed 100% antifungal activity after 10 days of treatment. After this period, the cultures taken from the infected region were inoculated and found negative results. For untreated rats, symptoms were observed at the same time as in treated animals and were present till the end of the experiment. In vivo experiment proved that isolated compound to be most effective against tested pathogens. Alkaloids present in the isolated compound believed to be a responsible constituent to this effect. This assumption was confirmed and reported that sterols, alkaloids, proteins, and carbohydrates show significant wound healing activity [39].

CONCLUSION
The phytochemical constituents and pharmacological activities proved that the isolated compound was found to be effective against human fungal pathogens and hence can be used as a base molecule in the design of new antifungal drugs.

ACKNOWLEDGMENT
The authors wish to thank the University Grants Commission, New Delhi, for providing financial assistance through Maulana Azad National fellowship. The authors are also thankful to Dr. Sheikh Rahber, Department of Chemistry, Gulbarga University, Kalaburagi, Karnataka, India, for characterization.

AUTHORS’ CONTRIBUTIONS
Vidyasagar GM designed the experiment and involved in the interpretation of data. Nuzhat Tabassum carried out the experimental work, analysis of data and manuscript preparation. Raghunandan and Shivakumar involved in in vivo activity. Authors went through the final manuscript.

CONFLICT OF INTEREST
There is no conflict of interest to declare.

AUTHOR’S FUNDING
This research received no external fundings.

REFERENCES
1. Savita S, Rao DV, Sharma RA. A review on Pongamia pinnata (L.) Pierre: A great value leguminous plant. Nat Sci 2010;8:130-9.
2. Chopade VV, Tankar AN, Pande VV, Tekade AR, Gowekar NM, Bhandari SR, Khandake SN. Pongamia pinnata: Phytochemical constituents, traditional uses and pharmacological properties: a review. Int J Green Pharm 2008;2:72-5.
3. Pankaj K, Rashesh P. An Phytochemical overview of various parts of Pongamia pinnata (Karanj). World J Pharm Res 2012;2:146-65.
4. Koyosomboon S, Altena IV, Kato S, Chantarapromma K. Antimycobacterial flavonoids from Derris indica. Phytochemistry 2006;67:1034-40.
5. Li LY, Li X, Shi C, Deng ZW, Fu HZ, Proksch P, et al. Pongamone A-E, five flavonoids from the stems of a mangrove plant, Pongamia pinnata. Phytochem 2006;67:1347-52.
6. Yin H, Wu J, Nan H, Zhang S. New prenylated flavones from Pongamia pinnata. Pharmazie 2006;61:78-6.
7. Ahmad G, Yadav PP, Maurya R. Furanoflavonoid glycosides from Pongamia pinnata fruits. Phytochemistry 2004;65:921-4.
8. Yadav PP, Ahmad G, Maurya R. Furanoflavonoids from Pongamia pinnata fruits. Phytochemistry 2004;65:439-43.
9. Carcacio-Blanco EJ, Kang YH, Park EJ, Su BN, Kardon LB, Riswan S, et al. Constituents of the stem bark of Pongamia pinnata with the potential to induce quinone reductase. J Nat Prod 2003;66:1197-202.
10. Simin K, Ali Z, Khaliqu-Uz-Zaman SM, Ahmad VU. Structure and biological activity of a new rotenoid from Pongamia pinnata. Nat Prod Lett 2002;16:351-7.
11. Chauhan D, Chauhan JS. Flavonoid glycosides from Pongamia pinnata. Pharm Biol 2002;40:171-4.
12. Tanaka T, Iinuma M, Yuki K, Fujiy Y, Mizuno M. Flavonoids in root bark of Pongamia pinnata. Phytochemistry 1992;31:993-8.
13. Tanaka T, Iinuma M, Yuki K, Fujiy Y, Mizuno M. Two new beta-hydroxycalcones from the root bark of Pongamia pinnata. Chem Pharm Bull 1991;39:1473-5.
14. Kanungo PD, Ganguly A, Guha A, Bhattacharyya A, Adityachaudhury N. Glabone, a new furanoflavonol from Pongamia glabra. Phytochemistry 1997;26:3737-4.
15. Pathak VP, Sainin TR, Kanna RN. Isopongochromene, a chromeno flavonol from pongamia glabra seeds. Phytochemistry 1983;22:308-9.
16. Talapatra SK, Malik AK, Talapatra B. Isopongaglabol and 6-methylisopongaglabol, two new hydroxyfurano flavonoids from Pongamia glabra. Phytochemistry 1982;21:761-6.
17. Rastogi RP, Mehotra BN. Compendium of Indian Medicinal Plant. New Delhi, India: Central Drug Research Institute and Publication and Information Directorate; 1993.
18. Talapatra SK, Malik AK, Talapatra B. Pongaglabol, a new hydroxyfurano flavonol, and aurantic acid, a dipeptide from the flowers of Pongamia glabra. Phytochemistry 1980;19:1199-202.
19. Ujwal P, Pramod KM, Raja NH, Hosetti BB. Antimicrobial activity of different extracts of Pongamia pinnata. Med Aromat Plant Sci Biotechnol 2007;1:285-7.
20. Davies J. Inactivation of antibiotic and the dissemination of resistance genes. Science 1994;264:375-82.
21. Hay RJ. Antifungal drugs used for systemic mycoses. Dermatol Clin 1993;11:577-89.
22. Marques SA, Robles AM, Tortorano AM, Tuculet MA, Negroni R, Mendes RP. Mycoses associated with AIDS in the Third World. Med Mycol 2000;38:269-79.
23. Lal AN, Patra DP, Trivedi B, Ghanta G, Reddy CV, Nisar A. Antifungal activity of extracts of some medicinal plants. J Ethnopharmacol 2009;120:34-9.
24. Lahiri C, Mukhopadhyay B, Bhattacharyya A. Furofuranocoumarins show significant wound healing activity [39].
25. Mandal SM, Barbosa AE, Franco OL. Lipopeptides in microbial infection control: Scope and reality for industry. Biotechnol Adv 2007;25:285-95.
26. Sarkar S, Maity S, Carcache-Blanco EJ, Kang YH, Park EJ, Su BN, Kardon LB, Riswan S, et al. Constituents of the stem bark of Pongamia pinnata with the potential to induce quinone reductase. J Nat Prod 2003;66:1197-202.
27. Simin K, Ali Z, Khaliqu-Uz-Zaman SM, Ahmad VU. Structure and biological activity of a new rotenoid from Pongamia pinnata. Nat Prod Lett 2002;16:351-7.
28. Carcacio-Blanco EJ, Kang YH, Park EJ, Su BN, Kardon LB, Riswan S, et al. Constituents of the stem bark of Pongamia pinnata with the potential to induce quinone reductase. J Nat Prod 2003;66:1197-202.
29. Simin K, Ali Z, Khaliqu-Uz-Zaman SM, Ahmad VU. Structure and biological activity of a new rotenoid from Pongamia pinnata. Nat Prod Lett 2002;16:351-7.
30. Carcacio-Blanco EJ, Kang YH, Park EJ, Su BN, Kardon LB, Riswan S, et al. Constituents of the stem bark of Pongamia pinnata with the potential to induce quinone reductase. J Nat Prod 2003;66:1197-202.
31. Simin K, Ali Z, Khaliqu-Uz-Zaman SM, Ahmad VU. Structure and biological activity of a new rotenoid from Pongamia pinnata. Nat Prod Lett 2002;16:351-7.
32. Seetharam YN, Kotresh K, Uplokar SB. Flora of Gulbarga District. Gulbarga: Gulbarga University; 2000.
33. Carcacio-Blanco EJ, Kang YH, Park EJ, Su BN, Kardon LB, Riswan S, et al. Constituents of the stem bark of Pongamia pinnata with the potential to induce quinone reductase. J Nat Prod 2003;66:1197-202.
34. Carcacio-Blanco EJ, Kang YH, Park EJ, Su BN, Kardon LB, Riswan S, et al. Constituents of the stem bark of Pongamia pinnata with the potential to induce quinone reductase. J Nat Prod 2003;66:1197-202.
35. Carcacio-Blanco EJ, Kang YH, Park EJ, Su BN, Kardon LB, Riswan S, et al. Constituents of the stem bark of Pongamia pinnata with the potential to induce quinone reductase. J Nat Prod 2003;66:1197-202.
36. Carcacio-Blanco EJ, Kang YH, Park EJ, Su BN, Kardon LB, Riswan S, et al. Constituents of the stem bark of Pongamia pinnata with the potential to induce quinone reductase. J Nat Prod 2003;66:1197-202.
37. Carcacio-Blanco EJ, Kang YH, Park EJ, Su BN, Kardon LB, Riswan S, et al. Constituents of the stem bark of Pongamia pinnata with the potential to induce quinone reductase. J Nat Prod 2003;66:1197-202.
53. Suryakant B, Kedarnath, Vishwanath C, Patil CS. Phytochemical activity of oils of Pongamia pinnata subsp. and Pongamia glabra. Indian J Chem 1997a;15:1138-9.

54. Pathak VP, Saini TR, Khanna RN. Chemical constituents of Pongamia pinnata seed. Phytochemistry 1983b;22:308.

55. Roy D, Sharma NN, Khanna RN. Structure and synthesis of iso pongalavone, a new component of the seeds of Pongamia glabra. Indian J Chem 1977a;15:1138-9.

56. Pathak VP, Saini TR, Khanna RN. Glabrachalcone, a chroomoneohalcone from Pongamia glabra seeds. Phytochemistry 1983a;22:1303-4.

57. Upadhya GS, Narayanaswami G, Kartha AR. Note on the comparative development of fatty acids in ripening seeds of 16 dicot species producing C16-C18 acid fats. Indian J Agric Sci 1974;44:620-2.

58. Rahul DY, Jain SK, Shashish A, Prapajati SK, Arif A. Vigna pinnata a new antioxidant. Int J Pharm Sci Res 2011;2:496.

59. Evans SV, Fellows LE, Bell EA. Distribution and systematic significance of basic non protein amino acids and amines in the Tephrosiae. Biochem Syst Ecol 1985;13:271-302.

60. Nawrat U, Gryzbek-Hryncewicz K, Karpiewska A. Susceptibility of Candida species to antifungal activity determined by micromethod method. Mikol Lek 2006;7:19-26.

61. Conner DE, Beuchat LR. Effects of essential oils from plants on growth of food spoilage yeast. J Food Sci 1984;49:429.

62. Hanafy MS, Hatem ME. Studies on the antimicrobial activity of Nigella sativa seed (black cumin). J Ethnopharm 1991;34:275-8.

63. Aggarwal R, Kharya MD, Srivastava R. Antimicrobial and antihelmintic activities of the essential oil of Nigella sativa Linn. Indian J Exp Biol 1979;17:1264-5.

64. Khan MA, Ashfaq MK, Zuberi HS, Mahmood MS, Gilani AH. The in vitro anti fungal activity of the aqueous extract from Nigella sativa seed. Phytother Res 2003;17:183-6.

65. Mashhadian NV, Rakhshandeh H. Antibacterial and antifungal effects of Nigella sativa extracts against S. aureus, P. aeroginosa and C. albicans. Pak J Med Sci 2005;21:47-9.

66. Singh VP, Singh HR, Singh RB. The fungicidal effect of neem extracts on some soil borne pathogens of gram (Cicer arietinum). Mycologia 1980;72:1077-93.

67. Dalleau S, Cateau E, Berges T, Berjeaud J, Limbert C. In vitro activity of essential oils and their major components against Candida albicans yeasts growing planktonically and as biofilms. Int J Antimicrob Agents 2007;29:147.

68. Kishore N, Mishra AK, Chansouria JP. Fungitoxicity of essential oils against dermatophytes. Mycoses 1993;36:211-5.

69. Morris JA, Khettry A, Seitz EW. Antimicrobial activity of aroma chemicals and essential oils. J Am Oil Chem Soc 1979;56:595-603.

70. Ross SA, El-Keltawi NE, Megalla SE. Antimicrobial activity of some Egyptian aromatic plants. Fitoterapia 1980;51:201-5.

71. Yousef RT, Tawil GG. Antimicrobial activity of volatile oils. Pharmazie 1985;40:704-7.

72. Hili P, Evans CS, Veness RG. In vitro activity of essential oils of A. thymus against human pathogenic fungi and food spoilage bacteria. Afr J Biotechnol 2001;51:201-5.

73. Charcheri S, Dahoun A, Bachi F, Benslimani A. In vitro antimicrobial activity of essential oils of Artemisia herba-alba and Artemisia judautca from Algeria. Riv Ital EPPO 1996;18:3-6.

74. Vijaya M, Cass I, Judy G, Nadeem A, Talpur B, Echard W, et al. Antifungal activity of essential oils against Candida albicans. Mol Cell Biochem 2001;228:111-7.

75. Nakamura CV, Iskida K, Facien LC, Filho BP, Cortez DA, Rozental S. In vitro activity of essential oil of Ocimum gratissimum L. against four Candida species. Res Microbiol 2004;155:579-86.

76. Shabnam J, Sobia M, Ibatsam K, Rauf A, Saleem MH. Comparative antimicrobial activity of clove and fennel essential oils against food borne pathogenic fungi and food spoilage bacteria. Afr J Biotechnol 2012;11:16065-70.

77. Sunita B, Mahendra R. Antifungal activity of essential oils from Indian medicinal plants against human pathogenic Aspergillus fumigatus and N. tigris. World J Med Sci 2008;3:81-8.

78. Sunawala FA, Garba SA, Mawak JD, Oyewole OA. Antimicrobial activity of Cymbopogon citratus (Lemon Grass) and its phytochemical properties. Front Sci 2012;2:214-20.

79. Fernanda CS, Sara MC, Virginia MS, Deila MS, Botelho NL, Luis RB. Evaluation of antifungal activity of essential oils against potentially fungicidal microorganisms. Curr Sci 2006;90:15-9.

80. Soliven FA. The proximate chemical composition of the seed and oil of Philippine oil-bearing seeds: I. Pongamia pinnata. Philippine Agric 1934b:25:576-87.

81. Pathak VP, Saini TR, Khanna RN. Chemical constituents of Pongamia pinnata seed. Phytochemistry 1983b;22:308.

82. Roy D, Sharma NN, Khanna RN. Structure and synthesis of iso pongalavone, a new component from the seeds of Pongamia glabra. Indian J Chem 1979;15:1138-9.

83. Pathak VP, Saini TR, Khanna RN. Glabrachalcone, a chroomoneohalcone from Pongamia glabra seeds. Phytochemistry 1983a;22:1303-4.

84. Upadhya GS, Narayanaswami G, Kartha AR. Note on the comparative development of fatty acids in ripening seeds of 16 dicot species producing C16-C18 acid fats. Indian J Agric Sci 1974;44:620-2.
mycotoxigenic \textit{Aspergillus flavus} and \textit{Aspergillus parasiticus}. Braz J Pharm 2012;22:1002-10.

88. Singh G, Sumitra M, Catalan C, Lampasona MP. Chemical, antifungal, antioxidant and sprout suppressant studies on ginger essential oil and its oleoresin. Flavour Fragr J 2005b;20:1-6.

89. Ogunkunle J, Tonia AL. Ethnobotanical and phytochemical studies on some species of Senna in Nigeria. Afr J Biotechnol 2006;5:2020-3.

90. Cowan MM. Plant products as antimicrobial agents. Clin Microbio Rev 1999;12:564-82.

91. Sulivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. Phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology (Reading) 1995;141:1507-21.

92. Coleman DC, Bennett DE, Sullivan DJ, Gallagher PJ, Henman MC, Shanley DB, \textit{et al.} Oral Candida in HIV infection and AIDS: New perspectives/new approaches. Crit Rev Microbiol 1993;19:61-82.

93. Sobel JD. Vulvovaginal candidosis. Lancet 2007;369:1961-71.

94. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995;8:240-59.